Mildronate (Meldonium Dihydrate)

Meldonium, the active ingredient in Mildronate, is a cardioprotective agent presented as an injectable solution for intravenous use. It helps shift myocardial energy metabolism toward glucose oxidation, supporting patients with ischemic heart disease, heart failure, angina and peripheral vascular disease.

GNH USA supplies Mildronate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, reliable logistics and regulatory support.

Mildronate is used in the management of cardiovascular conditions that involve reduced blood flow to the heart or peripheral tissues.

- Ischemic heart disease: improves myocardial energy efficiency and reduces angina symptoms. - Heart failure: supports cardiac output by enhancing glucose utilization. - Angina pectoris: decreases frequency and severity of chest‑pain episodes. - Peripheral vascular disease: aids tissue perfusion and reduces intermittent claudication.

Mildronate may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Nausea - Dizziness - Insomnia

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Hepatic enzyme elevation - Cardiac arrhythmia - Severe hypotension

When prescribing Mildronate, clinicians should consider several safety measures.

- Monitor cardiac function: assess ECG and symptoms regularly. - Evaluate liver enzymes: check hepatic function before and during therapy. - Use cautiously in renal impairment: adjust dosing if necessary. - Avoid in patients with known hypersensitivity to meldonium. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mildronate can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Concurrent use with strong anti‑arrhythmic agents: may increase risk of arrhythmias. - Combination with anticoagulants: potential for enhanced bleeding tendency. - Co‑administration with other carnitine‑modulating drugs: may blunt therapeutic effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: possible additive hypotensive effect. - Diuretics: monitor electrolyte balance. - Statins: observe for increased muscle toxicity.